Post
JAMA Internal Medicine
jamainternalmed.com
did:plc:inotdipik2f2wxvg7nk5pqll
RCT: Among 450 participants, Azelastine nasal spray was associated with a reduced incidence of lab-confirmed SARS-CoV-2 respiratory infections (2.2% compared to 6.7% with placebo). ja.ma/4lUgWos
2025-09-07T16:00:03.804Z